Poolbeg Pharma PLC announced that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug to treat a metabolic condition. Under the agreement, the Company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg's licensed oral delivery technology*. Poolbeg believes that this technology can help to optimise the delivery of its partner's novel drug to its ideal site of therapeutic action.

The Company is optimistic that this strategic collaboration can progress to a full licensing agreement in time, whereby the Nasdaq listed biopharma could integrate this novel oral delivery technology into its pipeline. This marks another significant milestone in Poolbeg's journey towards early revenues and underscores the Company's commitment to advancing treatments for metabolic conditions.